High Impact Clinical Research Support Program Report issue

Academic/Hospital Phase 1 Phase 2

Organization Overview

First Clinical Trial
2014
NCT01630590
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 1)

Carcinoma, Renal Cell (Phase 1)

Kidney Neoplasms (Phase 1)

Leukemia (Phase 1)

Leukemia, Myeloid (Phase 1)

Leukemia, Myeloid, Acute (Phase 1)

Prostatic Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 4
  • # of Trial APIs: 7